argenx SE (NASDAQ:ARGX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

argenx SE (NASDAQ:ARGX) has been given an average recommendation of “Moderate Buy” by the twenty-three research firms that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation, nineteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $630.42.

Several brokerages have recently issued reports on ARGX. Citigroup upped their price target on argenx from $512.00 to $635.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. William Blair raised argenx from a “market perform” rating to an “outperform” rating in a research note on Friday, November 1st. Oppenheimer reissued an “outperform” rating and issued a $675.00 target price (up previously from $646.00) on shares of argenx in a research note on Thursday, November 21st. Truist Financial increased their target price on argenx from $540.00 to $660.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft lowered argenx from a “buy” rating to a “hold” rating in a research note on Friday, October 4th.

argenx Stock Up 1.2 %

Shares of ARGX opened at $614.59 on Thursday. argenx has a 12-month low of $327.73 and a 12-month high of $620.28. The firm has a market capitalization of $37.10 billion, a PE ratio of -698.40 and a beta of 0.61. The stock’s fifty day simple moving average is $560.78 and its 200-day simple moving average is $492.76.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same quarter in the prior year, the firm posted ($1.25) earnings per share. Analysts anticipate that argenx will post 2.2 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. FMR LLC grew its holdings in shares of argenx by 35.9% during the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after buying an additional 1,265,486 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of argenx by 0.4% during the third quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company’s stock worth $1,343,797,000 after buying an additional 10,975 shares in the last quarter. Clearbridge Investments LLC grew its holdings in shares of argenx by 3.6% during the second quarter. Clearbridge Investments LLC now owns 617,466 shares of the company’s stock worth $265,535,000 after buying an additional 21,189 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of argenx by 13.0% during the third quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock worth $261,470,000 after buying an additional 55,617 shares in the last quarter. Finally, Sei Investments Co. grew its holdings in shares of argenx by 15.2% during the second quarter. Sei Investments Co. now owns 381,544 shares of the company’s stock worth $164,079,000 after buying an additional 50,477 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.